Structural Biology Initiative, CUNY Advanced Science Research Center, New York, NY 10031, USA; PhD Program in Biochemistry, CUNY Graduate Center, New York, NY 10016, USA.
Center for Free-Electron Laser Science CFEL, Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany; Institute for Nanostructure and Solid State Physics, Universität Hamburg, Hamburg, Germany; Division of Life Sciences, Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, UK.
Structure. 2024 Aug 8;32(8):1231-1238.e4. doi: 10.1016/j.str.2024.05.010. Epub 2024 Jun 10.
Due to their low binding affinities, detecting small-molecule fragments bound to protein structures from crystallographic datasets has been a challenge. Here, we report a trove of 65 new fragment hits for PTP1B, an "undruggable" therapeutic target enzyme for diabetes and cancer. These structures were obtained from computational analysis of data from a large crystallographic screen, demonstrating the power of this approach to elucidate many (∼50% more) "hidden" ligand-bound states of proteins. Our new structures include a fragment hit found in a novel binding site in PTP1B with a unique location relative to the active site, one that links adjacent allosteric sites, and, perhaps most strikingly, a fragment that induces long-range allosteric protein conformational responses. Altogether, our research highlights the utility of computational analysis of crystallographic data, makes publicly available dozens of new ligand-bound structures of a high-value drug target, and identifies novel aspects of ligandability and allostery in PTP1B.
由于它们的结合亲和力较低,因此从晶体学数据集检测与蛋白质结构结合的小分子片段一直是一个挑战。在这里,我们报告了针对 PTP1B 的 65 个新的片段命中,PTP1B 是糖尿病和癌症的一种“不可成药”的治疗靶标酶。这些结构是通过对大型晶体筛选数据的计算分析获得的,证明了这种方法能够阐明许多(约增加 50%)“隐藏”的配体结合状态的蛋白质。我们的新结构包括在 PTP1B 中一个独特的活性位点相关的新型结合位点中发现的片段命中,该片段与相邻的变构位点相连,最引人注目的是,一个诱导远程变构蛋白构象反应的片段。总的来说,我们的研究强调了晶体学数据的计算分析的实用性,公开了数十种高价值药物靶标的新的配体结合结构,并确定了 PTP1B 中配体结合和变构的新方面。